Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Athero-B-Cell

Financiado

Cerrado

Targeting and exploiting B cell functions for treatment in cardiovascular diseas...

Targeting and exploiting B cell functions for treatment in cardiovascular disease Cardiovascular disease (CVD) mortality and morbidity is predicted to increase in Europe and worldwide in the next decades due to aging and the rise of diabetes and obesity. The link between metabolic and inflammatory disease is ge... ver más

31/08/2018

UOXF

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-08-31 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

UOXF

0.00€ | Lider

UNIGE

N.D. | Participante

UNIVERSITY COLLEGE LONDON

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

The B-MIracle The function of B cells in myocardial infarction-accelerated... 1M€ Cerrado

CARDIOMIR Development of microRNA Medicines for Cardiac Metabolic Dise... 2M€ Cerrado

B-specific B-specific: B-cell related gene and protein markers with pro... 4M€ Cerrado

FROM BENCH TO BEDSIDE Role of microRNAs 143 and 145 in cardiovascular physiology a... 100K€ Cerrado

RYC-2009-04599 Análisis metabonómico de la expresión diferencial de miRNA e... 192K€ Cerrado

SYSVASC Systems Biology to Identify Molecular Targets for Vascular D... 8M€ Cerrado

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cardiovascular disease (CVD) mortality and morbidity is predicted to increase in Europe and worldwide in the next decades due to aging and the rise of diabetes and obesity. The link between metabolic and inflammatory disease is getting stronger, raising hopes for novel therapeutic targets to be exploited clinically. Clinical evidence generated by the Academic partners of the Athero-B-Cell Consortium demonstrates that CVD is associated with pro- and anti-atherogenic B cell responses. We aim to use existing proteomic, transcriptomic and miRNA data generated from large-scale clinical studies in previous EU-funded collaborative efforts to decipher the pathways that favor pro- and anti-atherogenic B cell functions in order to unravel a new set of therapeutic targets and refine potential vaccine strategies for CVD. The selection and validation of targets will be made possible by substantial technological advance achieved by the participating SMEs that are world leaders in the field of bioinformatics, genetic modification including humanised mouse models, and 3rd generation antisense drugs with locked nucleic-acid (LNA) design that are in Phase II human trials. Academia-led innovation includes high-resolution methodologies such as CyTOF and ImageStream to interrogate available samples from clinical trials and the ability to validate the targets of interest in accredited models of CVD. The validation in vivo and in vitro of such targets will feed into the SME pipeline accelerating the process of drug discovery. The recent clinical success of 3rd generation antisense drugs underscores the advantage of the Athero-B-Cell approach: the seamless transition from validation tools to clinical applications. Harnessing protective or abating unwanted B cell responses has the potential to improve health, innovation and competitiveness of European SME and Academia, while shedding light on the pathogenesis of CVD, the world's biggest killer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores